Skip to main content
  • Sign in
    Welcome !
    My account
    Logout

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Forecast 2025 - AI Price Prediction & Analysis

NEUROCRINE BIOSCIENCES INC (NBIX) AI Stock Price Forecast & Investment Analysis

NEUROCRINE BIOSCIENCES INC Stock Price Chart and Technical Analysis

Loading NEUROCRINE BIOSCIENCES INC interactive price chart and technical analysis...

NEUROCRINE BIOSCIENCES INC (NBIX) - Comprehensive Stock Analysis & Investment Research

Deep dive into NEUROCRINE BIOSCIENCES INC's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about NEUROCRINE BIOSCIENCES INC, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For NEUROCRINE BIOSCIENCES INC: NEUROCRINE BIOSCIENCES INC operates in the Life Sciences sector, positioning it as a large-cap market leader.

NEUROCRINE BIOSCIENCES INC (Stock Symbol: NBIX) is a leading company in the Life Sciences sector , specifically operating within the Biological Products, (No Diagnostic Substances) industry.

The organization employs approximately 400 professionals worldwide .

The company has established itself as a major market leader with significant institutional backing.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing NEUROCRINE BIOSCIENCES INC's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For NEUROCRINE BIOSCIENCES INC: With $2509M in annual revenue and 542.9% net margin, the company demonstrates exceptional profitability.

Annual Revenue: $2509 million generating a 542.9% net profit margin .

Market Capitalization: $14677 million - Classified as a large-cap stock with institutional-grade stability.

Return on Equity (ROE): 5.5% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for NEUROCRINE BIOSCIENCES INC stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

For NEUROCRINE BIOSCIENCES INC: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for NEUROCRINE BIOSCIENCES INC stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: NEUROCRINE BIOSCIENCES INC's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For NEUROCRINE BIOSCIENCES INC: Strong free cash flow generation demonstrates solid operational efficiency.

NEUROCRINE BIOSCIENCES INC strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace, positioning itself as a dominant large-cap market leader with significant competitive moats and institutional investor confidence .

The company demonstrates robust operational efficiency through strong free cash flow generation of $102 million annually, complemented by impressive 50.3% year-over-year cash flow growth.

The company maintains a healthy 2930.4% gross margin, indicating strong pricing power and operational efficiency.

NEUROCRINE BIOSCIENCES INC (NBIX) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for NEUROCRINE BIOSCIENCES INC stock analysis.

Loading NEUROCRINE BIOSCIENCES INC comprehensive fundamental analysis and insider trading data...

Deep dive into NEUROCRINE BIOSCIENCES INC's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if NEUROCRINE BIOSCIENCES INC stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For NEUROCRINE BIOSCIENCES INC: With a P/E ratio of 42.14, the market highly values future growth prospects.

P/E Ratio 42.14x
P/B Ratio 5.45x
Market Cap $14677M
EPS $3.48
Book Value/Share $26.47
Revenue/Share $24.66
FCF/Share $2.38
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently NEUROCRINE BIOSCIENCES INC converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For NEUROCRINE BIOSCIENCES INC: An ROE of 5.5% indicates room for improvement in shareholder value creation.

ROE 5.5%
ROA 3.6%
ROIC 5.0%
Gross Margin 2930.4%
Operating Margin 814.2%
Net Margin 542.9%
EBT Margin 7.9%
Tax Rate 25.3%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess NEUROCRINE BIOSCIENCES INC's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For NEUROCRINE BIOSCIENCES INC: A current ratio of 4.02 indicates strong liquidity.

Current Ratio 4.02x
Quick Ratio 3.66x
D/E Ratio 0.35x
Financial Leverage 1.54x
Interest Coverage 5.4x
Working Capital $830M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal NEUROCRINE BIOSCIENCES INC's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For NEUROCRINE BIOSCIENCES INC: Free cash flow of $102M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $128M
Free Cash Flow $102M
Capital Spending $-27M
OCF Growth YoY 50.3%
FCF Growth YoY 58.5%
FCF/Sales 8.5%
CapEx/Sales 2.2%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively NEUROCRINE BIOSCIENCES INC uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For NEUROCRINE BIOSCIENCES INC: An asset turnover of 0.61x suggests room for improvement in asset utilization.

Asset Turnover 0.61x
Receivables Turnover 5.9x
Inventory Turnover 0.5x
Fixed Assets Turnover 8.0x
Days Sales Outstanding 62 days
Days Inventory 674 days
Payables Period 1160 days
Cash Conversion Cycle -358 days
Understanding Financial Statement Data

What these metrics mean: Key figures from NEUROCRINE BIOSCIENCES INC's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For NEUROCRINE BIOSCIENCES INC: With annual revenue of $2509M, NEUROCRINE BIOSCIENCES INC operates at significant scale.

Income Statement ($ Millions)
Total Revenue $2509M
R&D Expense $38M
SG&A Expense $54M
Cost of Goods Sold $34M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 47%
Cash & Short-term Investments 31%
Total Liabilities 35%
Short-term Debt 31%
Accounts Receivable 12%
Inventory 1%
Dividend & Shareholder Information
Shares Outstanding 102M
Growth Metrics (YoY)
EPS Growth 3.0%

Latest NEUROCRINE BIOSCIENCES INC Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting NEUROCRINE BIOSCIENCES INC (NBIX) stock price and investment outlook.

📰 We are currently updating our news feed for NEUROCRINE BIOSCIENCES INC. Check back soon for the latest market analysis and company updates.

NEUROCRINE BIOSCIENCES INC Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of NEUROCRINE BIOSCIENCES INC against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS Unlock Forecast - 30 Days FREE Trial $85M -1.9x 0.7x
ABP Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
ABPWW Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
ACLX Unlock Forecast - 30 Days FREE Trial $3725M -74.1x 8.9x
ACOG Unlock Forecast - 30 Days FREE Trial $143M x 4.5x
ADAP Unlock Forecast - 30 Days FREE Trial $65M -13.2x -11.8x
ADMA Unlock Forecast - 30 Days FREE Trial $4028M 19.3x 10.1x
ADPT Unlock Forecast - 30 Days FREE Trial $1959M -4.6x 10.9x
ADVM Unlock Forecast - 30 Days FREE Trial $58M -1.8x 2.2x
AGEN Unlock Forecast - 30 Days FREE Trial $130M -0.5x -0.5x
AIM Unlock Forecast - 30 Days FREE Trial $2M -0.5x -183.3x
AIMI Unlock Forecast - 30 Days FREE Trial $2M x x
ALEC Unlock Forecast - 30 Days FREE Trial $305M -1.2x 4.3x
ALGS Unlock Forecast - 30 Days FREE Trial $107M -19.2x 1.1x
ALLO Unlock Forecast - 30 Days FREE Trial $253M -1.4x 0.7x
ALVR Unlock Forecast - 30 Days FREE Trial $49M -0.5x 0.4x
AMGN Unlock Forecast - 30 Days FREE Trial $151464M 22.9x 20.4x
APGE Unlock Forecast - 30 Days FREE Trial $2215M -20.5x 4.3x
APTO Unlock Forecast - 30 Days FREE Trial $6M 0.0x -1.3x
APTOF Unlock Forecast - 30 Days FREE Trial $3M x x
ARMP Unlock Forecast - 30 Days FREE Trial $103M -1.0x -1.6x
ARTV Unlock Forecast - 30 Days FREE Trial $88M x 0.6x
ATHA Unlock Forecast - 30 Days FREE Trial $15M -0.2x 0.5x
ATRA Unlock Forecast - 30 Days FREE Trial $149M 25.8x -1.1x
ATYR Unlock Forecast - 30 Days FREE Trial $515M -3.6x 6.9x
AURA Unlock Forecast - 30 Days FREE Trial $402M -4.9x 2.3x
AUTL Unlock Forecast - 30 Days FREE Trial $389M x 1.1x
AVXL Unlock Forecast - 30 Days FREE Trial $876M -17.3x 9.6x
BCAB Unlock Forecast - 30 Days FREE Trial $125M -1.1x 1.0x
BCDA Unlock Forecast - 30 Days FREE Trial $12M -0.6x -7.8x
BCLI Unlock Forecast - 30 Days FREE Trial $7M -4.9x -0.9x
BCRX Unlock Forecast - 30 Days FREE Trial $1802M -12.1x -4.0x
BDTX Unlock Forecast - 30 Days FREE Trial $171M 11.8x 1.3x
BEAM Unlock Forecast - 30 Days FREE Trial $2060M -12.6x 2.0x
BIIB Unlock Forecast - 30 Days FREE Trial $18125M 12.8x 1.5x
BKHA Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
BKHAU Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
BLUE Unlock Forecast - 30 Days FREE Trial $49M -0.2x -0.8x
CABA Unlock Forecast - 30 Days FREE Trial $155M -1.6x 0.9x
CADL Unlock Forecast - 30 Days FREE Trial $338M -4.6x 4.5x
CCCC Unlock Forecast - 30 Days FREE Trial $193M -2.6x 1.1x
CDTX Unlock Forecast - 30 Days FREE Trial $728M -1.0x 5.1x
CELZ Unlock Forecast - 30 Days FREE Trial $9M -3.4x 1.3x
CERO Unlock Forecast - 30 Days FREE Trial $2M x -196.2x
CEROW Unlock Forecast - 30 Days FREE Trial $2M x -0.5x
CGEM Unlock Forecast - 30 Days FREE Trial $449M -4.1x 0.8x
CGEN Unlock Forecast - 30 Days FREE Trial $134M x 2.7x
CGON Unlock Forecast - 30 Days FREE Trial $2532M x 3.8x
CGTX Unlock Forecast - 30 Days FREE Trial $170M -0.5x 24.1x
CHRO Unlock Forecast - 30 Days FREE Trial $8M x -2.0x
CHRS Unlock Forecast - 30 Days FREE Trial $150M 0.8x 1.3x
CLDI Unlock Forecast - 30 Days FREE Trial $5M -0.9x 3.1x
CMPX Unlock Forecast - 30 Days FREE Trial $483M -4.8x 5.2x
COEPW Unlock Forecast - 30 Days FREE Trial $M x x
CRBU Unlock Forecast - 30 Days FREE Trial $174M -1.5x 1.1x
CRDF Unlock Forecast - 30 Days FREE Trial $144M -4.0x 2.5x
CRGX Unlock Forecast - 30 Days FREE Trial $215M x 0.9x
CRIS Unlock Forecast - 30 Days FREE Trial $18M -0.3x -2.9x
CRSP Unlock Forecast - 30 Days FREE Trial $4745M -12.1x 2.8x
CSBR Unlock Forecast - 30 Days FREE Trial $111M -17.8x 20.4x
CVM Unlock Forecast - 30 Days FREE Trial $56M -0.9x 8.0x
CYTH Unlock Forecast - 30 Days FREE Trial $26M -0.6x -1.9x
CYTHW Unlock Forecast - 30 Days FREE Trial $7M x -0.5x
DBVT Unlock Forecast - 30 Days FREE Trial $1479M -3.3x 514.8x
DNA Unlock Forecast - 30 Days FREE Trial $568M -13.9x 0.3x
DNLI Unlock Forecast - 30 Days FREE Trial $2111M -8.7x 1.9x
DTIL Unlock Forecast - 30 Days FREE Trial $59M -2.2x 1.7x
DYAI Unlock Forecast - 30 Days FREE Trial $28M -7.3x 11.4x
EDIT Unlock Forecast - 30 Days FREE Trial $231M -0.8x 3.7x
ELEV Unlock Forecast - 30 Days FREE Trial $22M -1.0x 0.5x
ELUT Unlock Forecast - 30 Days FREE Trial $84M -1.4x -0.1x
ENGN Unlock Forecast - 30 Days FREE Trial $276M 3.7x 1.2x
ENGNW Unlock Forecast - 30 Days FREE Trial $37M x 0.1x
ENTX Unlock Forecast - 30 Days FREE Trial $94M 8.5x 5.4x
ENZ Unlock Forecast - 30 Days FREE Trial $25M -3.0x 0.5x
ENZB Unlock Forecast - 30 Days FREE Trial $37M x 0.8x
ESLA Unlock Forecast - 30 Days FREE Trial $39M -3.1x -16.9x
ESLAW Unlock Forecast - 30 Days FREE Trial $4M x 5.3x
EXEL Unlock Forecast - 30 Days FREE Trial $10959M 18.2x 5.4x
EXOZ Unlock Forecast - 30 Days FREE Trial $100M x 13.9x
FATE Unlock Forecast - 30 Days FREE Trial $115M -1.3x 0.4x
FDMT Unlock Forecast - 30 Days FREE Trial $406M -3.0x 1.0x
FENC Unlock Forecast - 30 Days FREE Trial $250M 1758.3x -39.7x
FNCH Unlock Forecast - 30 Days FREE Trial $20M -0.1x 1.4x
FTII Unlock Forecast - 30 Days FREE Trial $-26M x -0.7x
FTIIU Unlock Forecast - 30 Days FREE Trial $-26M x -0.8x
FTIIW Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
GILD Unlock Forecast - 30 Days FREE Trial $145510M 23.1x 7.4x
GLUE Unlock Forecast - 30 Days FREE Trial $398M 16.5x 1.5x
GNTA Unlock Forecast - 30 Days FREE Trial $64M x 5.1x
GPLB Unlock Forecast - 30 Days FREE Trial $M x x
HALO Unlock Forecast - 30 Days FREE Trial $9543M 17.1x 28.7x
HLVX Unlock Forecast - 30 Days FREE Trial $105M -0.6x 0.7x
HUMA Unlock Forecast - 30 Days FREE Trial $224M -3.3x 55.2x
HUMAW Unlock Forecast - 30 Days FREE Trial $163M x -2.6x
IBRX Unlock Forecast - 30 Days FREE Trial $2427M -3.6x -4.1x
IKNA Unlock Forecast - 30 Days FREE Trial $61M -1.3x 0.5x
IKT Unlock Forecast - 30 Days FREE Trial $150M -1.0x 1.9x
IMCR Unlock Forecast - 30 Days FREE Trial $1809M x 4.7x
IMVT Unlock Forecast - 30 Days FREE Trial $2851M -14.5x 4.7x
INAB Unlock Forecast - 30 Days FREE Trial $21M -0.4x 2.4x
INBX Unlock Forecast - 30 Days FREE Trial $436M -6.8x 6.4x
INKT Unlock Forecast - 30 Days FREE Trial $59M -1.5x -1.4x
INMB Unlock Forecast - 30 Days FREE Trial $52M -2.5x 1.8x
INTS Unlock Forecast - 30 Days FREE Trial $7M -2.2x 3.4x
IOVA Unlock Forecast - 30 Days FREE Trial $851M -4.5x 1.2x
IPSC Unlock Forecast - 30 Days FREE Trial $44M -0.7x 0.2x
ITOS Unlock Forecast - 30 Days FREE Trial $393M -2.8x 0.7x
IVVD Unlock Forecast - 30 Days FREE Trial $137M -0.4x 3.2x
IZTC Unlock Forecast - 30 Days FREE Trial $99M x -27.5x
JSPR Unlock Forecast - 30 Days FREE Trial $44M -3.2x 1.9x
JSPRW Unlock Forecast - 30 Days FREE Trial $3M x 0.0x
KLRS Unlock Forecast - 30 Days FREE Trial $86M x 1.6x
KLTO Unlock Forecast - 30 Days FREE Trial $26M x 2.4x
KLTOW Unlock Forecast - 30 Days FREE Trial $1M x 0.4x
KOD Unlock Forecast - 30 Days FREE Trial $556M -2.5x 7.9x
KRBPQ Unlock Forecast - 30 Days FREE Trial $0M x x
KRYS Unlock Forecast - 30 Days FREE Trial $4211M 28.7x 4.1x
KYMR Unlock Forecast - 30 Days FREE Trial $3459M -17.8x 3.6x
KYTX Unlock Forecast - 30 Days FREE Trial $170M x 0.9x
LADX Unlock Forecast - 30 Days FREE Trial $M x x
LCTX Unlock Forecast - 30 Days FREE Trial $271M -4.7x 5.6x
LENZ Unlock Forecast - 30 Days FREE Trial $1141M -6.7x 5.5x
LIMN Unlock Forecast - 30 Days FREE Trial $0M x x
LXEO Unlock Forecast - 30 Days FREE Trial $271M -0.4x 2.0x
MAZE Unlock Forecast - 30 Days FREE Trial $696M x 2.7x
MGTX Unlock Forecast - 30 Days FREE Trial $693M -3.4x 20.9x
MGX Unlock Forecast - 30 Days FREE Trial $72M x 0.4x
MRNA Unlock Forecast - 30 Days FREE Trial $9519M -3.2x 1.0x
NBIX Unlock Forecast - 30 Days FREE Trial $14677M 42.1x 5.5x
NKGN Unlock Forecast - 30 Days FREE Trial $4M -0.1x -0.2x
NKGNW Unlock Forecast - 30 Days FREE Trial $1M x 0.0x
NMRA Unlock Forecast - 30 Days FREE Trial $271M -3.9x 1.5x
NVAX Unlock Forecast - 30 Days FREE Trial $1417M 3.4x 37.7x
OCGN Unlock Forecast - 30 Days FREE Trial $298M -4.3x 18.7x
OMGA Unlock Forecast - 30 Days FREE Trial $9M -0.7x 0.8x
OMGAQ Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
ONVO Unlock Forecast - 30 Days FREE Trial $35M -0.4x 95.9x
OTLK Unlock Forecast - 30 Days FREE Trial $73M -0.2x -2.3x
PALI Unlock Forecast - 30 Days FREE Trial $4M -0.2x 0.7x
PASG Unlock Forecast - 30 Days FREE Trial $23M -0.6x 0.6x
PCVX Unlock Forecast - 30 Days FREE Trial $4445M -20.4x 1.5x
PHGE Unlock Forecast - 30 Days FREE Trial $14M 1.5x 0.7x
PLUR Unlock Forecast - 30 Days FREE Trial $-4M -1.4x -9.1x
PLX Unlock Forecast - 30 Days FREE Trial $120M 19.1x 2.4x
PMCB Unlock Forecast - 30 Days FREE Trial $7M -2.6x 0.2x
PRME Unlock Forecast - 30 Days FREE Trial $500M -1.5x 8.2x
PROK Unlock Forecast - 30 Days FREE Trial $-61M x 0.0x
PSTX Unlock Forecast - 30 Days FREE Trial $926M -9.6x 10.6x
PTHS Unlock Forecast - 30 Days FREE Trial $M x x
QGEN Unlock Forecast - 30 Days FREE Trial $10571M x 3.0x
QNCX Unlock Forecast - 30 Days FREE Trial $86M -1.7x 7.4x
REPL Unlock Forecast - 30 Days FREE Trial $932M -3.8x 2.2x
RGEN Unlock Forecast - 30 Days FREE Trial $6531M 8219.1x 3.3x
RGNX Unlock Forecast - 30 Days FREE Trial $499M -1.8x 2.3x
RLAY Unlock Forecast - 30 Days FREE Trial $707M -2.0x 1.1x
RVMD Unlock Forecast - 30 Days FREE Trial $7134M -11.1x 3.4x
RVMDW Unlock Forecast - 30 Days FREE Trial $16M x 0.0x
RXRX Unlock Forecast - 30 Days FREE Trial $2020M -4.7x 2.2x
SABS Unlock Forecast - 30 Days FREE Trial $24M -2.3x 1.1x
SABSW Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
SANA Unlock Forecast - 30 Days FREE Trial $719M -2.1x 5.9x
SCLX Unlock Forecast - 30 Days FREE Trial $62M -0.4x -0.3x
SCLXW Unlock Forecast - 30 Days FREE Trial $25M x -0.1x
SCNI Unlock Forecast - 30 Days FREE Trial $9674M -287.8x 1231.2x
SGMO Unlock Forecast - 30 Days FREE Trial $131M -1.6x 6.7x
SLDB Unlock Forecast - 30 Days FREE Trial $495M -0.9x 1.7x
SLXN Unlock Forecast - 30 Days FREE Trial $4M x 34.5x
SLXNW Unlock Forecast - 30 Days FREE Trial $866M x -189.1x
SNTI Unlock Forecast - 30 Days FREE Trial $51M -1.1x 1.3x
SRRK Unlock Forecast - 30 Days FREE Trial $4069M -18.5x 13.0x
SRZN Unlock Forecast - 30 Days FREE Trial $105M -0.5x 2.2x
SRZNW Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
STRO Unlock Forecast - 30 Days FREE Trial $90M -1.0x -2.5x
SWTX Unlock Forecast - 30 Days FREE Trial $3539M -9.9x 8.5x
TARA Unlock Forecast - 30 Days FREE Trial $131M -2.1x 0.9x
TARS Unlock Forecast - 30 Days FREE Trial $2328M -12.4x 7.0x
TCBP Unlock Forecast - 30 Days FREE Trial $37M x 34.5x
TCBPW Unlock Forecast - 30 Days FREE Trial $1M x 1.0x
TCBPY Unlock Forecast - 30 Days FREE Trial $13M x 12.0x
TCRX Unlock Forecast - 30 Days FREE Trial $248M -4.6x 1.4x
TECH Unlock Forecast - 30 Days FREE Trial $8155M 75.2x 4.0x
TECX Unlock Forecast - 30 Days FREE Trial $314M -8.9x 1.1x
TIL Unlock Forecast - 30 Days FREE Trial $182M -1.1x 1.3x
TNYA Unlock Forecast - 30 Days FREE Trial $184M -2.5x 1.9x
TRML Unlock Forecast - 30 Days FREE Trial $688M -3.5x 2.7x
TSBX Unlock Forecast - 30 Days FREE Trial $8M -0.1x 0.6x
TSHA Unlock Forecast - 30 Days FREE Trial $919M -3.0x 3.7x
TTNP Unlock Forecast - 30 Days FREE Trial $8M -0.5x 4.5x
TVGN Unlock Forecast - 30 Days FREE Trial $168M x -29.3x
TVGNW Unlock Forecast - 30 Days FREE Trial $11M x -1.9x
TWST Unlock Forecast - 30 Days FREE Trial $1478M -12.6x 3.1x
VACH Unlock Forecast - 30 Days FREE Trial $-1436M x 0.0x
VACHU Unlock Forecast - 30 Days FREE Trial $-1585M x 0.0x
VCEL Unlock Forecast - 30 Days FREE Trial $1566M 220.4x 5.1x
VIGL Unlock Forecast - 30 Days FREE Trial $384M -1.1x 9.3x
VIR Unlock Forecast - 30 Days FREE Trial $732M -2.0x 0.8x
VIVS Unlock Forecast - 30 Days FREE Trial $3M x 0.3x
VOR Unlock Forecast - 30 Days FREE Trial $246M -0.6x 3.9x
VXRT Unlock Forecast - 30 Days FREE Trial $87M -0.9x 2.7x
VYGR Unlock Forecast - 30 Days FREE Trial $248M 570.6x 1.0x
WINT Unlock Forecast - 30 Days FREE Trial $18M -0.4x 4.2x
XFOR Unlock Forecast - 30 Days FREE Trial $8M 6.4x 0.4x
ZIVO Unlock Forecast - 30 Days FREE Trial $57M -31.3x -2.0x
ZURA Unlock Forecast - 30 Days FREE Trial $131M 5.0x 0.9x

Frequently Asked Questions - NEUROCRINE BIOSCIENCES INC Stock Forecast

How accurate are NEUROCRINE BIOSCIENCES INC stock predictions?

Our AI model demonstrates 48% historical accuracy for NBIX predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence NEUROCRINE BIOSCIENCES INC stock price forecasts?

Our analysis considers NEUROCRINE BIOSCIENCES INC's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is NEUROCRINE BIOSCIENCES INC a good investment in 2025?

Based on our AI analysis, NEUROCRINE BIOSCIENCES INC shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are NEUROCRINE BIOSCIENCES INC forecasts updated?

NEUROCRINE BIOSCIENCES INC stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced NEUROCRINE BIOSCIENCES INC Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for NEUROCRINE BIOSCIENCES INC stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...